Anavex Life Sciences Corp.

NASDAQ:AVXL

Biotechnology

Healthcare
$0.72 -1.67%

-$0.04 today

Market cap
$66.69M
Beta
1.12
P/E (TTM)
-5.9
EPS (TTM)
-$0.45
52W Low $2.41High $13.99

Volume 1.06M

Average 1.39M

AVXL Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

Anavex Life Sciences Corp.NASDAQ: AVXL

Depreciation & Amortization · Q1 FY2026 · quarter ended Dec 2025

Depreciation & amortization remains negative

Q1 FY2026 depreciation & amortization was $0, compared with $0 a year earlier. Trailing-twelve-month depreciation & amortization was $0.

Context

  • Depreciation & amortization increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly depreciation & amortization holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterDec 2025
$0— QoQ
Last fiscal yearSep 2025
$0— YoY
LTMDec 2025
$0— YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—

Depreciation & Amortization vs competitors

How AVXL compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
AVXL Competitors
Depreciation & Amortization for AVXL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RGNXREGENXBIO Inc.LTM Mar 2026$15.52M USD-3.0%+6.5%17.7%
MGTXMeiraGTx Holdings plcLTM Mar 2026$12.82M USD+2.6%+13.6%16.1%
ABSIAbsci CorporationLTM Mar 2026$11.4M USD-12.6%-3.4%620.8%
VALNValneva SELTM Mar 2026€6.46M EUR-64.9%+1.1%4.1%
ARVNArvinas, Inc.LTM Mar 2026$4.5M USD-21.1%-14.1%5.0%
MLTXMoonLake ImmunotherapeuticsLTM Mar 2026$3.08M USD+50.1%+151.3%—
ERASErasca, Inc.LTM Sep 2026$2.89M USD-9.4%+5.6%—
CTMXCytomX Therapeutics, Inc.LTM Mar 2026$1.24M USD-26.3%-17.4%3.5%
MBXMBX Biosciences, Inc. Common StockLTM Sep 2026$343K USD+39.4%+64.2%—
AVXLAnavex Life Sciences Corp.LTM Dec 2025$0 USD———
Peer median (excluding AVXL) —-9.4%+5.6%10.6%

Competitors are the stored peer set for AVXL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Sep 2021
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development32.98M37.92M43.72M41.84M37.59M
Selling, General & Admin9.02M13.07M12.05M11.04M13.82M
Operating Expenses42M50.99M55.76M52.88M51.41M
Depreciation & Amortization00000
EBITDA(37.64M)(47.62M)(46.54M)(43M)(46.38M)
EBITDA Margin—————
Operating Income(42M)(50.99M)(55.76M)(52.88M)(51.41M)
Operating Margin—————
Interest Income26K947K6.52M7.32M4.68M
Interest Expense00964K00
Other Income / Expenses4.36M3.37M8.26M9.88M5.03M
Income Before Tax(37.64M)(47.62M)(47.51M)(43M)(46.38M)
Pre-Tax Margin—————
Income Tax Expense268K358K000
Net Income(37.91M)(47.98M)(47.51M)(43M)(46.38M)
Net Margin—————
EPS (Basic)(0.54)(0.62)(0.60)(0.52)(0.54)
EPS (Diluted)(0.54)(0.62)(0.60)(0.52)(0.54)
Weighted Avg Shares69.8M76.91M79.79M83.47M85.29M
Weighted Avg Shares (Diluted)69.8M76.91M79.79M83.47M85.29M

Anavex Life Sciences Corp.

NASDAQ:AVXL

Intrinsic Alpha fair value

Locked

Current Price

$0.72

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.